Regarding the participation of British researchers in Horizon 2020 projects, UK Research and Innovation’s (UKRI) Brussels-based UK Research Office (UKRO) is maintaining and regularly updating a factsheet providing the latest information on the current situation.
An interview of Benjamin Falcon (LMB team) entitled "Spotlight on early-career investigators: an interview with Benjamin Falcon" was published this month on Neuronet, the European network on Neurodegeneration research.
NEURONET is a three-year coordination and support action that kicked off in March 2019. The aim of NEURONET is to set up an efficient platform to boost collaboration across research projects focusing on neurodegenerative diseases, including but not limited to Alzheimer’s disease.
Enjoy browsing this new site which also links to a network of existing IMI projects in the field, amongst which IMPRiND is proud to be.
Congratulations! IMPRiND consortium member Michel Goedert @MichelGoed is awarded the 2019 Royal Medal for Biological Sciences.
Michel has been honoured for his work on neurodegenerative diseases, especially for identifying and characterising key molecules that form the inclusions of Alzheimer’s and Parkinson’s diseases which he also carries out in the frame of the IMPRiND project.
More information can be found on the website of the MRC Laboratory of Molecular Biology (LMB).
On May 30 a paper by Luc Bousset and Ronald Melki on two new polymorphic structures of alpha-synuclein solved by cryo-electron microscopy was published in bioRxiv. Access to the article.
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.
The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.